1. New Zealand. Pholcodine: benefit-risk review,2019
2. IgE-sensitisation to the cough suppressant pholcodine and the effects of its withdrawal from the Norwegian market;Florvaag;Allergy,2011
3. Six years without pholcodine; Norwegians are significantly less IgE-sensitized and clinically more tolerant to neuromuscular blocking agents;de Pater;Allergy,2017
4. Pholcodine consumption increases the risk of perioperative anaphylaxis to neuromuscular blocking agents: the ALPHO case-control study. [Preprint.];Mertes;medRxiv,2022
5. Available from: www.ema.europa.eu/en/medicines/human/referrals/pholcodine-containing-medicinal-products (accessed 21 March 2023). European Medicines Agency statement on withdrawal of pholcodine-containing products.